In the News

Genetic Engineering & Biotechnology News

August 20, 2018

Follow
Harbour BioMed
on WeChat

Back to list

Genetic Engineering & Biotechnology News

August 20, 2018

Harbour BioMed will partner with Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize its Phase II cancer immunotherapy candidate A167 worldwide except greater China, through an exclusive collaboration that could generate more than $350 million for Kelun-Biotech, the companies said today.

Media Contact:

Harbour BioMed Public Relations

E-mail: pr@harbourbiomed.com